Ligand Pharma (LGND) Misses Q4 EPS by 45c
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $274.88 --0%
Revenue Growth %: +33.3%
Financial Fact:
Research and development: 5.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +33.3%
Financial Fact:
Research and development: 5.9M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q4 EPS of $0.74, $0.45 worse than the analyst estimate of $1.19. Revenue for the quarter came in at $38.2 million versus the consensus estimate of $40.34 million.
GUIDANCE:
Ligand Pharma sees FY2017 EPS of $2.70.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Goldman Sachs Starts Infratil New Zealand (IFT:NZ) at Buy
- Berenberg Downgrades Umicore SA (UMI:BB) (UMICY) to Hold
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
